InvestLog
KYNB Kyntra Bio, Inc. logo

KYNB Kyntra Bio, Inc.

Healthcare
$6.99+0.72%ClosedMarket Cap: $28.3M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

0.16

PEG

0.00

P/B

-3.05

P/S

3.80

EV/EBITDA

0.19

DCF Value

$11.13

FCF Yield

-75.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

26.7%

Operating Margin

-596.2%

Net Margin

1498.0%

ROE

-182.1%

ROA

101.7%

ROIC

-54.0%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$3.7M$-15.2M$—
Q4 null$1.3M$-14.2M$—
FY null$6.4M$183.5M$—
Q3 null$1.1M$148.5M$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$28.00

Target (Median)

$28.00

Target Range

$28.00 - $28.00

0 Strong Buy1 Buy1 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2025-09-24
HC Wainwright & Co.Buy
2025-08-07

Trading Activity

Insider Trades

View All
Wettig Thanedirector, officer: CEO
BuyTue May 19
Wettig Thanedirector, officer: CEO
BuyMon May 18
Wettig Thanedirector, officer: CEO
SellTue Mar 10
DeLucia Davidofficer: Chief Financial Officer
SellTue Mar 10
Wettig Thanedirector, officer: CEO
SellThu Feb 05

Company Info

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Country

US

Exchange

—

Beta

1.04

Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

Peers

ALGS logoALGSATNM logoATNMCELU logoCELUKZR logoKZRMRSN logoMRSNOKUR logoOKURPDSB logoPDSBTPST logoTPSTXFOR logoXFORXLO logoXLO